Glaukos Corporation (GKOS) Stock Analysis

Glaukos Advances Eye Care Portfolio with Three-Year Epioxa Trial Data and Licensing Deal

Thu, October 8, 2026 at 4:49 PM UTC 3 min read

Glaukos Corporation (GKOS) announced the advancement of its eye care portfolio through the release of three-year data from its Epioxa trial, which demonstrated promising long-term results for its glaucoma treatment. Additionally, the company secured a licensing deal that could enhance its product offerings and market position. This development is significant for investors as it underscores Glaukos' commitment to innovation and potential revenue growth in the ophthalmic sector.

Read full article →

Glaukos Partners with NBA Champion Stephen Curry to Launch "Could it be KC?" Campaign to Raise Awareness of Keratoconus

Wed, September 23, 2026 at 11:00 AM UTC 2 min read

Glaukos Corporation has partnered with NBA champion Stephen Curry to launch the "Could it be KC?" campaign aimed at raising awareness of keratoconus, a progressive eye disease. This initiative not only highlights Glaukos' commitment to addressing unmet medical needs but also enhances its brand visibility, potentially attracting new investors and patients. The collaboration with a high-profile athlete may further strengthen Glaukos' market position and drive interest in its innovative treatment solutions.

Read full article →